Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Cancer Diagnostic Device

Published: Thursday, May 29, 2014
Last Updated: Thursday, May 29, 2014
Bookmark and Share
Commercial launch of a new system to improve cancer diagnosis and treatment.

This week sees the commercial launch of a new cancer diagnostic device developed by Clearbridge BioMedics in partnership with product development firm Cambridge Consultants.

The ClearCell FX System is able to isolate and capture circulating tumour cells (CTCs) from a blood sample - even at concentrations as low as one in a billion blood cells. This is crucial for both research and clinical purposes, as CTCs play a significant role in metastasis - the main cause of cancer-related deaths.

Cambridge Consultants helped to translate Singapore-based Clearbridge Biomedics’ design into a commercial prototype. “This commercial launch of the ClearCell FX System marks a new milestone in the project after a successful transfer from design and development to manufacturing,” said John Pritchard, head of diagnostics at Cambridge Consultants.

“It’s the latest example of our expertise in the design and development of diagnostic instrumentation, coupled with our long track record of helping clients bring innovative products to market fast. In this case it has helped create a device that has the potential to increase understanding of cancer - and, ultimately, improve patient care.”

The ClearCell FX System uses biomechanical properties to isolate intact, viable CTCs, making it label free - i.e. without biochemical markers. The fully-automated system integrates with downstream assays - making it simple to use and saving both time and manpower.

The device is highly sensitive and enables researchers to achieve reproducible results. It is designed to help cancer researchers better study CTCs and cancer metastasis biology - and potentially develop new cancer treatments.

With the ClearCell FX System, a simple blood test could provide clinicians and researchers with real-time monitoring of a patient’s cancer progression. This is critical as cancers are complex, heterogenous and constantly evolving with each treatment and over time.

“At Clearbridge BioMedics we aim to bring clarity to cancer, by allowing each and every patient to benefit from timely, tailored treatment,” said Johnson Chen, managing director of Clearbridge BioMedics. “Real-time monitoring of a patient’s CTCs allows clinicians to develop the best treatment at the right time. By matching treatments to the patient, they benefit from optimal treatment outcomes, with fewer negative side effects and lower costs.”

The ClearCell FX System is already being used by the Circulating Tumour Cell Centre of Research Excellence (CTC CoRE) - a collaboration between Clearbridge BioMedics, the National Cancer Centre Singapore and the pathology department at Singapore General Hospital.

"The ClearCell FX System allows us to reproducibly retrieve CTCs from a routine blood test, opening up new possibilities for applying molecular diagnostic tests that have become crucial in managing cancer patients,” said Dr Daniel Tan, consultant, Division of Medical Oncology at the National Cancer Centre Singapore.

“Beyond improving patient stratification, such minimally invasive tools provide unique vistas into studying the characteristics of cancer cells in circulation. It is anticipated that the CTC CoRE will bring together state-of-the-art microfluidic technologies, next-generation molecular diagnostics and cutting-edge clinical science - ultimately to improve cancer care.”

The ClearCell FX System will be showcased at the annual meeting of the American Society of Clinical Oncology (ASCO), May 30 to June 3, in Chicago.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Era in Cancer Diagnostics
Novel development for improved cancer diagnosis and treatment monitoring.
Tuesday, June 04, 2013
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Discovered Through ‘Big Data’ Analysis
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Cell Cargo Ships in Near Future?
Virus-inspired container design may lead to cell cargo ships following construction of ten large, two-component, icosahedral protein complexes.
Uncovering a New Principle in Chemotherapy Resistance in Breast Cancer
The NIH study has revealed an entirely unexpected process for acquiring drug resistance that bypasses the need to re-establish DNA damage repair in breast cancers that have mutant BRCA1 or BRCA2 genes.
Understanding Treatment Resistant Melanoma
Researchers have determined how advanced melanoma becomes resistant; a development toward developing treatments.
Liquid Biopsies: DNA Size Matters
Study finds circulating tumour DNA can be distinguished from healthy DNA through fragment size identification.
Unravelling the Roots of Insect’s Waterproof Coating
Researchers have identified the genes that control cuticular lipid production in Drosophila, by performing an RNAi screen and using Direct Analysis in Real Time and GC-MS.
Identifying Cancer Drug Targets Using 3D-Modelling
Researchers are now able to model genetic mutations manipulation of proteins that can potentially drive cancer.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!